Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.
Advertisement
Nature Reviews Cardiology (2025)
Metrics details
Cannabis has been consumed for centuries, but global regulatory changes over the past three decades have increased the availability and consumption of cannabis. Cannabinoids are touted to have therapeutic potential for many diseases and could be a replacement for opioids for analgesia and sedation. However, cannabinoids can cause substantial adverse cardiovascular events that would mitigate any potential benefit. The endocannabinoid system regulates mood, satiety and memory, and modulates the cardiovascular system. The link between cannabinoids and cardiovascular disease, which used to be limited to evidence from preclinical studies, case reports and case series, is now evident in epidemiological studies. Cannabinoids adversely affect the cardiovascular system, causing myocardial infarction, cerebrovascular accidents, arrhythmia and heart failure. The effects of novel cannabinoids are unknown, and synthetic cannabinoids have the potential to cause even more substantial harm than traditional cannabinoids. Therefore, with the increasing availability and use of cannabis, the acute and chronic effects of this drug are becoming apparent.
Cannabis use has increased as a result of decriminalization and legalization, but the cardiovascular effects need research to inform public health policies.
Cannabis, via cannabinoid receptor 1 (CB1)-mediated oxidative stress and inflammation, is linked to adverse cardiovascular outcomes, including myocardial infarction, arrhythmias and cardiomyopathy.
CB1 antagonists and CB2 agonists are promising novel treatments for cardiovascular risk factors and cardiovascular disease, but clinical translation is complicated by adverse effects and limited data.
Synthetic cannabinoids (such as ‘K2’ and ‘Spice’) are an emerging public health concern owing to their potent toxicity and cardiovascular implications.
The co-use of cannabis and tobacco has synergistic adverse effects on cardiovascular health and addiction potential.
Induced pluripotent stem cell modelling and genetic tools should be used to discover novel cannabinoid signalling pathways and potential new therapeutic targets for cardiometabolic disease.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
Prices may be subject to local taxes which are calculated during checkout
Page, R. L. et al. Medical marijuana, recreational cannabis, and cardiovascular health: a scientific statement from the American Heart Association. Circulation 142, e131–e152 (2020).
Article PubMed Google Scholar
Chandy, M. et al. Adverse impact of cannabis on human health. Annu. Rev. Med. 75, 353–367 (2024).
Article PubMed Google Scholar
Bridgeman, M. B. & Abazia, D. T. Medicinal cannabis: history, pharmacology, and implications for the acute care setting. P T 42, 180–188 (2017).
PubMed PubMed Central Google Scholar
Ryan, J. E., McCabe, S. E. & Boyd, C. J. Medicinal cannabis: policy, patients, and providers. Policy Polit. Nurs. Pract. 22, 126–133 (2021).
Article PubMed PubMed Central Google Scholar
Hoffman, A. F. & Lupica, C. R. Synaptic targets of Δ9-tetrahydrocannabinol in the central nervous system. Cold Spring Harb. Perspect. Med. 3, a012237 (2013).
Article PubMed PubMed Central Google Scholar
Krishna Kumar, K. et al. Structure of a signaling cannabinoid receptor 1-G protein complex. Cell 176, 448–458.e12 (2019).
Article PubMed Google Scholar
Sugamura, K. et al. Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 119, 28–36 (2009).
Article PubMed Google Scholar
Netherland, C. D., Pickle, T. G., Bales, A. & Thewke, D. P. Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. Atherosclerosis 213, 102–108 (2010).
Article PubMed PubMed Central Google Scholar
Hoyer, F. F. et al. Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J. Mol. Cell Cardiol. 51, 1007–1014 (2011).
Article PubMed Google Scholar
Pacher, P., Steffens, S., Haskó, G., Schindler, T. H. & Kunos, G. Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly. Nat. Rev. Cardiol. 15, 151–166 (2018).
Article PubMed Google Scholar
Whiting, P. F. et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA 313, 2456–2473 (2015).
Article PubMed Google Scholar
Bilbao, A. & Spanagel, R. Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications. BMC Med. 20, 259 (2022).
Article PubMed PubMed Central Google Scholar
Bicket, M. C., Stone, E. M. & McGinty, E. E. Use of cannabis and other pain treatments among adults with chronic pain in US states with medical cannabis programs. JAMA Netw. Open. 6, e2249797 (2023).
Article PubMed PubMed Central Google Scholar
Zehra, A. et al. Cannabis addiction and the brain: a review. J. Neuroimmune Pharmacol. 13, 438–452 (2018).
Article PubMed PubMed Central Google Scholar
Secades-Villa, R., Garcia-Rodriguez, O., Jin, C. J., Wang, S. & Blanco, C. Probability and predictors of the cannabis gateway effect: a national study. Int. J. Drug. Policy 26, 135–142 (2015).
Article PubMed Google Scholar
Volkow, N. D., Baler, R. D., Compton, W. M. & Weiss, S. R. Adverse health effects of marijuana use. N. Engl. J. Med. 370, 2219–2227 (2014).
Article PubMed PubMed Central Google Scholar
Wei, T. T. et al. Cannabinoid receptor 1 antagonist genistein attenuates marijuana-induced vascular inflammation. Cell 185, 1676–1693.e23 (2022).
Article PubMed PubMed Central Google Scholar
DeFilippis, E. M. et al. Cocaine and marijuana use among young adults with myocardial infarction. J. Am. Coll. Cardiol. 71, 2540–2551 (2018).
Article PubMed PubMed Central Google Scholar
Patton, D. V. A history of United States cannabis law. J. Law Health 34, 1–29 (2020).
PubMed Google Scholar
Hall, W. et al. Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. Lancet 394, 1580–1590 (2019).
Article PubMed Google Scholar
Mead, A. Legal and regulatory issues governing cannabis and cannabis-derived products in the United States. Front. Plant. Sci. 10, 697 (2019).
Article PubMed PubMed Central Google Scholar
Lampe, J. R. Legal consequences of rescheduling marijuana. Congressional Research Service crsreports.congress.gov/product/pdf/LSB/LSB11105 (2024).
Shirah, B. H., Ahmed, M. M. & Saleh, R. A. in Medicinal Usage of Cannabis and Cannabinoids (eds Preedy, V. R., Patel, V. B. & Martin, C. R.) Ch. 5, 51–61 (Academic Press, 2023).
Bahji, A. & Stephenson, C. International perspectives on the implications of cannabis legalization: a systematic review & thematic analysis. Int. J. Env. Res. Public. Health 16, 3095 (2019).
Article Google Scholar
Rotermann, M. What has changed since cannabis was legalized? Health Rep. 31, 11–20 (2020).
PubMed Google Scholar
Martins, S. S. et al. Racial and ethnic differences in cannabis use following legalization in US states with medical cannabis laws. JAMA Netw. Open. 4, e2127002 (2021).
Article PubMed PubMed Central Google Scholar
Chemtob, D. Forbes Daily: The Budding $28B Hemp Market’s Feud with Marijuana. Forbes www.forbes.com/sites/daniellechemtob/2024/04/19/forbes-daily-the-budding-28b-hemp-markets-feud-with-marijuana/ (2024).
Fischer, B., Jutras-Aswad, D. & Hall, W. Outcomes associated with nonmedical cannabis legalization policy in Canada: taking stock at the 5-year mark. CMAJ 195, E1351–E1353 (2023).
Article PubMed PubMed Central Google Scholar
Chong, W. W., Acar, Z. I., West, M. L. & Wong, F. A scoping review on the medical and recreational use of cannabis during the COVID-19 pandemic. Cannabis Cannabinoid Res. 7, 591–602 (2022).
Article PubMed PubMed Central Google Scholar
Mackie, K. Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol. 46, 101–122 (2006).
Article PubMed Google Scholar
Movahed, P. et al. Vascular effects of anandamide and N-acylvanillylamines in the human forearm and skin microcirculation. Br. J. Pharmacol. 146, 171–179 (2005).
Article PubMed PubMed Central Google Scholar
Pacher, P., Batkai, S. & Kunos, G. Cardiovascular pharmacology of cannabinoids. Handb. Exp. Pharmacol. 599-625 (2005).
Pacher, P., Batkai, S. & Kunos, G. Blood pressure regulation by endocannabinoids and their receptors. Neuropharmacology 48, 1130–1138 (2005).
Article PubMed PubMed Central Google Scholar
Batkai, S. et al. Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am. J. Physiol. Heart Circ. Physiol 293, H1689–H1695 (2007).
Article PubMed Google Scholar
Valenta, I. et al. Feasibility evaluation of myocardial cannabinoid type 1 receptor imaging in obesity: a translational approach. JACC Cardiovasc. Imaging 11, 320–332 (2018).
Article PubMed PubMed Central Google Scholar
Rajesh, M. et al. Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 61, 716–727 (2012).
Article PubMed PubMed Central Google Scholar
Mukhopadhyay, P. et al. Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J. Am. Coll. Cardiol. 50, 528–536 (2007).
Article PubMed PubMed Central Google Scholar
Mukhopadhyay, P. et al. CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc. Res. 85, 773–784 (2010).
Article PubMed Google Scholar
Rajesh, M. et al. Cannabinoid receptor 2 activation alleviates diabetes-induced cardiac dysfunction, inflammation, oxidative stress, and fibrosis. Geroscience 44, 1727–1741 (2022).
Article PubMed PubMed Central Google Scholar
Matyas, C. et al. Interplay of liver–heart inflammatory axis and cannabinoid 2 receptor signaling in an experimental model of hepatic cardiomyopathy. Hepatology 71, 1391–1407 (2020).
Article PubMed Google Scholar
Molica, F. et al. Cannabinoid receptor CB2 protects against balloon-induced neointima formation. Am. J. Physiol. Heart Circ. Physiol 302, H1064–H1074 (2012).
Article PubMed PubMed Central Google Scholar
Koivisto, A. P., Belvisi, M. G., Gaudet, R. & Szallasi, A. Advances in TRP channel drug discovery: from target validation to clinical studies. Nat. Rev. Drug. Discov. 21, 41–59 (2022).
Article PubMed Google Scholar
Pertwee, R. G. Receptors and channels targeted by synthetic cannabinoid receptor agonists and antagonists. Curr. Med. Chem. 17, 1360–1381 (2010).
Article PubMed PubMed Central Google Scholar
Després, J. P., Golay, A. & Sjöström, L. Rimonabant in Obesity-Lipids Study Group Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. 353, 2121–2134 (2005).
Article PubMed Google Scholar
Onakpoya, I. J., Heneghan, C. J. & Aronson, J. K. Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis. Crit. Rev. Toxicol. 46, 477–489 (2016).
Article PubMed Google Scholar
Cinar, R., Iyer, M. R. & Kunos, G. The therapeutic potential of second and third generation CB1R antagonists. Pharmacol. Ther. 208, 107477 (2020).
Article PubMed PubMed Central Google Scholar
Crater, G. D., Lalonde, K., Ravenelle, F., Harvey, M. & Despres, J. P. Effects of CB1R inverse agonist, INV-202, in patients with features of metabolic syndrome. A randomized, placebo-controlled, double-blind phase 1b study. Diabetes Obes. Metab. 26, 642–649 (2024).
Article PubMed Google Scholar
Hashiesh, H. M., Sharma, C., Goyal, S. N., Jha, N. K. & Ojha, S. Pharmacological properties, therapeutic potential and molecular mechanisms of JWH133, a CB2 receptor-selective agonist. Front. Pharmacol. 12, 702675 (2021).
Article PubMed PubMed Central Google Scholar
Kosar, M. et al. Patent review of cannabinoid receptor type 2 (CB2R) modulators (2016–present). Expert. Opin. Ther. Pat. 34, 665–700 (2024).
Article PubMed Google Scholar
Smoum, R. et al. Editorial: therapeutic potential of the cannabinoid CB2 receptor. Front. Pharmacol. 13, 1039564 (2022).
Article PubMed PubMed Central Google Scholar
Morales, P., Hernandez-Folgado, L., Goya, P. & Jagerovic, N. Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update. Expert. Opin. Ther. Pat. 26, 843–856 (2016).
Article PubMed Google Scholar
Oparil, S. et al. Hypertension. Nat. Rev. Dis. Primers 4, 18014 (2018).
Article PubMed PubMed Central Google Scholar
Alshaarawy, O. & Elbaz, H. A. Cannabis use and blood pressure levels: United States National Health and Nutrition Examination Survey, 2005–2012. J. Hypertens. 34, 1507–1512 (2016).
Article PubMed PubMed Central Google Scholar
Golosova, D., Levchenko, V., Kravtsova, O., Palygin, O. & Staruschenko, A. Acute and long-term effects of cannabinoids on hypertension and kidney injury. Sci. Rep. 12, 6080 (2022).
Article PubMed PubMed Central Google Scholar
Sultan, S. R., Millar, S. A., O’Sullivan, S. E. & England, T. J. A systematic review and meta-analysis of the in vivo haemodynamic effects of Δ8-tetrahydrocannabinol. Pharmaceuticals 11, 13 (2018).
Article PubMed PubMed Central Google Scholar
Intengan, H. D. & Schiffrin, E. L. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension 36, 312–318 (2000).
Article PubMed Google Scholar
Corroon, J., Grant, I., Bradley, R. & Allison, M. A. Trends in cannabis use, blood pressure, and hypertension in middle-aged adults: findings from NHANES, 2009–2018. Am. J. Hypertens. 36, 651–659 (2023).
Article PubMed PubMed Central Google Scholar
Vallee, A. Association between cannabis use and blood pressure levels according to comorbidities and socioeconomic status. Sci. Rep. 13, 2069 (2023).
Article PubMed PubMed Central Google Scholar
Batkai, S. et al. Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension. Circulation 110, 1996–2002 (2004).
Article PubMed PubMed Central Google Scholar
Godlewski, G. et al. Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. Chem. Biol. 17, 1256–1266 (2010).
Article PubMed PubMed Central Google Scholar
Wagner, J. A. et al. Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. Nature 390, 518–521 (1997).
Article PubMed Google Scholar
Varga, K., Wagner, J. A., Bridgen, D. T. & Kunos, G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 12, 1035–1044 (1998).
Article PubMed Google Scholar
Batkai, S. et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat. Med. 7, 827–832 (2001).
Article PubMed Google Scholar
Ros, J. et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 122, 85–93 (2002).
Article PubMed Google Scholar
Shan, R. et al. Activation of cannabinoid type 2 receptor in microglia reduces neuroinflammation through inhibiting aerobic glycolysis to relieve hypertension. Biomolecules 14, 333 (2024).
Article PubMed PubMed Central Google Scholar
Guo, Y. et al. Cannabidiol protects against acute aortic dissection by inhibiting macrophage infiltration and PMAIP1-induced vascular smooth muscle cell apoptosis. J. Mol. Cell Cardiol. 189, 38–51 (2024).
Article PubMed Google Scholar
Curioni, C. & Andre, C. Rimonabant for overweight or obesity. Cochrane Database Syst. Rev. 2006, CD006162 (2006).
PubMed PubMed Central Google Scholar
Vidot, D. C. et al. Metabolic syndrome among marijuana users in the United States: an analysis of National Health and Nutrition Examination Survey data. Am. J. Med. 129, 173–179 (2016).
Article PubMed Google Scholar
Mousavi, S. E., Tondro Anamag, F. & Sanaie, S. Association between cannabis use and risk of diabetes mellitus type 2: a systematic review and meta-analysis. Phytother. Res. 37, 5092–5108 (2023).
Article PubMed Google Scholar
Ravi, D., Ghasemiesfe, M., Korenstein, D., Cascino, T. & Keyhani, S. Associations between marijuana use and cardiovascular risk factors and outcomes: a systematic review. Ann. Intern. Med. 168, 187–194 (2018).
Article PubMed PubMed Central Google Scholar
Despres, J. P. et al. Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler. Thromb. Vasc. Biol. 29, 416–423 (2009).
Article PubMed Google Scholar
Muniyappa, R. et al. Metabolic effects of chronic cannabis smoking. Diabetes Care 36, 2415–2422 (2013).
Article PubMed PubMed Central Google Scholar
Casier, I., Vanduynhoven, P., Haine, S., Vrints, C. & Jorens, P. G. Is recent cannabis use associated with acute coronary syndromes? An illustrative case series. Acta Cardiol. 69, 131–136 (2014).
Article PubMed Google Scholar
Jeffers, A. M., Glantz, S., Byers, A. L. & Keyhani, S. Association of cannabis use with cardiovascular outcomes among US adults. J. Am. Heart Assoc. 13, e030178 (2024).
Article PubMed PubMed Central Google Scholar
Frost, L., Mostofsky, E., Rosenbloom, J. I., Mukamal, K. J. & Mittleman, M. A. Marijuana use and long-term mortality among survivors of acute myocardial infarction. Am. Heart J. 165, 170–175 (2013).
Article PubMed Google Scholar
Libby, P. Inflammation in atherosclerosis. Nature 420, 868–8743 (2002).
Article PubMed Google Scholar
Rajesh, M. et al. Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br. J. Pharmacol. 160, 688–700 (2010).
Article PubMed PubMed Central Google Scholar
El-Remessy, A. B. et al. Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line. Diabetologia 54, 1567–1578 (2011).
Article PubMed PubMed Central Google Scholar
Paik, D. T., Chandy, M. & Wu, J. C. Patient and disease-specific induced pluripotent stem cells for discovery of personalized cardiovascular drugs and therapeutics. Pharmacol. Rev. 72, 320–342 (2020).
Article PubMed PubMed Central Google Scholar
Yang, Z., Kulkarni, K., Zhu, W. & Hu, M. Bioavailability and pharmacokinetics of genistein: mechanistic studies on its ADME. Anticancer. Agents Med. Chem. 12, 1264–1280 (2012).
Article PubMed PubMed Central Google Scholar
Dol-Gleizes, F. et al. Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 29, 12–18 (2009).
Article PubMed Google Scholar
Steffens, S. et al. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434, 782–786 (2005).
Article PubMed Google Scholar
Perez-Reyes, M., Owens, S. M. & Di Guiseppi, S. The clinical pharmacology and dynamics of marihuana cigarette smoking. J. Clin. Pharmacol. 21, 201S–207S (1981).
Article PubMed Google Scholar
Huestis, M. A. Human cannabinoid pharmacokinetics. Chem. Biodivers. 4, 1770–1804 (2007).
Article PubMed PubMed Central Google Scholar
Holt, A. et al. Cannabis for chronic pain: cardiovascular safety in a nationwide Danish study. Eur. Heart J. 45, 475–484 (2024).
Article PubMed Google Scholar
Patel, R. S., Gonzalez, M. D., Ajibawo, T. & Baweja, R. Cannabis use disorder and increased risk of arrhythmia-related hospitalization in young adults. Am. J. Addict. 30, 578–584 (2021).
Article PubMed Google Scholar
Chouairi, F. et al. Cannabis use disorder among atrial fibrillation admissions, 2008-2018. Pacing Clin. Electrophysiol. 44, 1934–1938 (2021).
Article PubMed Google Scholar
Gillett, L. et al. Arrhythmic effects of cannabis in ischemic heart disease. Cannabis Cannabinoid Res. 8, 867–876 (2023).
Article PubMed PubMed Central Google Scholar
Richards, J. R. Mechanisms for the risk of acute coronary syndrome and arrhythmia associated with phytogenic and synthetic cannabinoid use. J. Cardiovasc. Pharmacol. Ther. 25, 508–522 (2020).
Article PubMed Google Scholar
Kariyanna, P. T. et al. Marijuana induced myocarditis: a new entity of toxic myocarditis. Am. J. Med. Case Rep. 6, 169–172 (2018).
Article Google Scholar
Khanji, M. Y. et al. Association between recreational cannabis use and cardiac structure and function. JACC Cardiovasc. Imaging 13, 886–888 (2020).
Article PubMed Google Scholar
Bene-Alhasan, Y. et al. Daily marijuana use is associated with incident heart failure: “All of Us” research program [abstract]. Circulation 148 (Suppl. 1), 13812 (2023).
Google Scholar
Chen, B. et al. Endothelial cannabinoid CB1 receptor deficiency reduces arterial inflammation and lipid uptake in response to atheroprone shear stress. Preprint at bioRxiv, https://doi.org/10.1101/2024.05.15.594375 (2024).
Mukhopadhyay, P. et al. Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free. Radic. Biol. Med. 50, 179–195 (2011).
Article PubMed Google Scholar
Slavic, S. et al. Cannabinoid receptor 1 inhibition improves cardiac function and remodelling after myocardial infarction and in experimental metabolic syndrome. J. Mol. Med. 91, 811–823 (2013).
Article PubMed Google Scholar
Defer, N. et al. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J. 23, 2120–2130 (2009).
Article PubMed Google Scholar
McPartland, J. M., Duncan, M., Di Marzo, V. & Pertwee, R. G. Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br. J. Pharmacol. 172, 737–753 (2015).
Article PubMed PubMed Central Google Scholar
Alfulaij, N. et al. Cannabinoids, the heart of the matter. J. Am. Heart Assoc. 7, e009099 (2018).
Article PubMed PubMed Central Google Scholar
Lee, W. S. et al. Cannabidiol limits T cell-mediated chronic autoimmune myocarditis: implications to autoimmune disorders and organ transplantation. Mol. Med. 22, 136–146 (2016).
Article PubMed PubMed Central Google Scholar
Hao, E. et al. Cannabidiol protects against doxorubicin-induced cardiomyopathy by modulating mitochondrial function and biogenesis. Mol. Med. 21, 38–45 (2015).
Article PubMed PubMed Central Google Scholar
Rajesh, M. et al. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J. Am. Coll. Cardiol. 56, 2115–2125 (2010).
Article PubMed PubMed Central Google Scholar
Hampson, A. J., Grimaldi, M., Axelrod, J. & Wink, D. Cannabidiol and (–)Δ9-tetrahydrocannabinol are neuroprotective antioxidants. Proc. Natl Acad. Sci. USA 95, 8268–8273 (1998).
Article PubMed PubMed Central Google Scholar
Pacher, P., Kogan, N. M. & Mechoulam, R. Beyond THC and endocannabinoids. Annu. Rev. Pharmacol. Toxicol. 60, 637–659 (2020).
Article PubMed Google Scholar
Gonca, E. & Darici, F. The effect of cannabidiol on ischemia/reperfusion-induced ventricular arrhythmias: the role of adenosine A1 receptors. J. Cardiovasc. Pharmacol. Ther. 20, 76–83 (2015).
Article PubMed Google Scholar
Stanley, C. P., Hind, W. H., Tufarelli, C. & O’Sullivan, S. E. Cannabidiol causes endothelium-dependent vasorelaxation of human mesenteric arteries via CB1 activation. Cardiovasc. Res. 107, 568–578 (2015).
Article PubMed PubMed Central Google Scholar
Kumric, M., Bozic, J., Dujic, G., Vrdoljak, J. & Dujic, Z. Chronic effects of effective oral cannabidiol delivery on 24-h ambulatory blood pressure and vascular outcomes in treated and untreated hypertension (HYPER-H21-4): study protocol for a randomized, placebo-controlled, and crossover study. J. Pers. Med. 12, 1037 (2022).
Article PubMed PubMed Central Google Scholar
National Conference of State Legislatures. State Medical Cannabis Laws NCSL www.ncsl.org/health/state-medical-cannabis-laws (2024).
Balachandran, P., Elsohly, M. & Hill, K. P. Cannabidiol interactions with medications, illicit substances, and alcohol: a comprehensive review. J. Gen. Intern. Med. 36, 2074–2084 (2021).
Article PubMed PubMed Central Google Scholar
Moore, A., Straube, S., Fisher, E. & Eccleston, C. Cannabidiol (CBD) products for pain: ineffective, expensive, and with potential harms. J. Pain 25, 833–842 (2024).
Article PubMed Google Scholar
Bhat, T. A., Kalathil, S. G., Goniewicz, M. L., Hutson, A. & Thanavala, Y. Not all vaping is the same: differential pulmonary effects of vaping cannabidiol versus nicotine. Thorax 78, 922–932 (2023).
Article PubMed Google Scholar
Rossheim, M. E., LoParco, C. R., Henry, D., Trangenstein, P. J. & Walters, S. T. Delta-8, delta-10, HHC, THC-O, THCP, and THCV: what should we call these products? J. Stud. Alcohol. Drugs 84, 357–360 (2023).
Article PubMed Google Scholar
O’Mahony, B., O’Malley, A., Kerrigan, O. & McDonald, C. HHC-induced psychosis: a case series of psychotic illness triggered by a widely available semisynthetic cannabinoid. Ir. J. Psychol. Med. https://doi.org/10.1017/ipm.2024.3 (2024).
Article PubMed Google Scholar
Harlow, A. F., Miech, R. A. & Leventhal, A. M. Adolescent Δ8-THC and marijuana use in the US. JAMA 331, 861–865 (2024).
Article PubMed PubMed Central Google Scholar
Govindarajan, R. K. et al. Biosynthesis of phytocannabinoids and structural insights: a review. Metabolites 13, 442 (2023).
Article PubMed PubMed Central Google Scholar
Raup-Konsavage, W. M. et al. Efficient synthesis for altering side chain length on cannabinoid molecules and their effects in chemotherapy and chemotherapeutic induced neuropathic pain. Biomolecules 12, 1869 (2022).
Article PubMed PubMed Central Google Scholar
Nachnani, R., Raup-Konsavage, W. M. & Vrana, K. E. The pharmacological case for cannabigerol. J. Pharmacol. Exp. Ther. 376, 204–212 (2021).
Article PubMed Google Scholar
Peters, E. N. et al. Pharmacokinetics of cannabichromene in a medical cannabis product also containing cannabidiol and Δ9-tetrahydrocannabinol: a pilot study. Eur. J. Clin. Pharmacol. 78, 259–265 (2022).
Article PubMed Google Scholar
Abioye, A. et al. Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes. J. Cannabis Res. 2, 6 (2020).
Article PubMed PubMed Central Google Scholar
Jadoon, K. A. et al. Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel group pilot study. Diabetes Care 39, 1777–1786 (2016).
Article PubMed Google Scholar
Dziemitko, S., Harasim-Symbor, E. & Chabowski, A. How do phytocannabinoids affect cardiovascular health? An update on the most common cardiovascular diseases. Ther. Adv. Chronic Dis. 14, 20406223221143239 (2023).
Article PubMed PubMed Central Google Scholar
DeFilippis, E. M. et al. Marijuana use in patients with cardiovascular disease: JACC review topic of the week. J. Am. Coll. Cardiol. 75, 320–332 (2020).
Article PubMed PubMed Central Google Scholar
Bedi, G., Cooper, Z. D. & Haney, M. Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict. Biol. 18, 872–881 (2013).
Article PubMed Google Scholar
Zongo, A. et al. Medical cannabis authorization and the risk of cardiovascular events: a longitudinal cohort study. BMC Cardiovasc. Disord. 21, 426 (2021).
Article PubMed PubMed Central Google Scholar
Devinsky, O. et al. Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome. N. Engl. J. Med. 378, 1888–1897 (2018).
Article PubMed Google Scholar
Devinsky, O. et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N. Engl. J. Med. 376, 2011–2020 (2017).
Article PubMed Google Scholar
Ahmed, A. et al. Effects of digoxin at low serum concentrations on mortality and hospitalization in heart failure: a propensity-matched study of the DIG trial. Int. J. Cardiol. 123, 138–146 (2008).
Article PubMed Google Scholar
Lee, K. et al. Cannabidiol exposure during gestation leads to adverse cardiac outcomes early in postnatal life in male rat offspring. Cannabis Cannabinoid Res. 9, 781–796 (2024).
Article PubMed Google Scholar
D’hooghe, M. et al. Sativex(R) (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: the Belgian experience. BMC Neurol. 21, 227 (2021).
Article PubMed PubMed Central Google Scholar
Nurmikko, T. J. et al. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain 133, 210–220 (2007).
Article PubMed Google Scholar
Adams, A. J. et al. “Zombie” outbreak caused by the synthetic cannabinoid AMB-FUBINACA in New York. N. Engl. J. Med. 376, 235–242 (2017).
Article PubMed Google Scholar
Fantegrossi, W. E., Moran, J. H., Radominska-Pandya, A. & Prather, P. L. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: mechanism underlying greater toxicity? Life Sci. 97, 45–54 (2014).
Article PubMed Google Scholar
Hermanns-Clausen, M. et al. Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. Clin. Toxicol. 56, 404–411 (2018).
Article Google Scholar
Mir, A., Obafemi, A., Young, A. & Kane, C. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics 128, e1622–e1627 (2011).
Article PubMed Google Scholar
Jayakumar, N. et al. Co-use and mixing tobacco with cannabis among Ontario adults. Nicotine Tob. Res. 23, 171–178 (2021).
Article PubMed Google Scholar
Wu, T. C., Tashkin, D. P., Djahed, B. & Rose, J. E. Pulmonary hazards of smoking marijuana as compared with tobacco. N. Engl. J. Med. 318, 347–351 (1988).
Article PubMed Google Scholar
Hancox, R. J. et al. Effects of cannabis on lung function: a population-based cohort study. Eur. Respir. J. 35, 42–47 (2010).
Article PubMed Google Scholar
Tan, W. C. et al. The effects of marijuana smoking on lung function in older people. Eur. Respir. J. 54, 1900826 (2019).
Article PubMed Google Scholar
Crosland, B. A. et al. Risk of adverse neonatal outcomes after combined prenatal cannabis and nicotine exposure. JAMA Netw. Open. 7, e2410151 (2024).
Article PubMed PubMed Central Google Scholar
Hammond, C. J. et al. Co-occurring tobacco and cannabis use in adolescents: dissociable relationships with mediofrontal electrocortical activity during reward feedback processing. Neuroimage Clin. 30, 102592 (2021).
Article PubMed PubMed Central Google Scholar
Vogel, E. A., Rubinstein, M. L., Prochaska, J. J. & Ramo, D. E. Associations between marijuana use and tobacco cessation outcomes in young adults. J. Subst. Abuse Treat. 94, 69–73 (2018).
Article PubMed PubMed Central Google Scholar
Panlilio, L. V., Solinas, M., Matthews, S. A. & Goldberg, S. R. Previous exposure to THC alters the reinforcing efficacy and anxiety-related effects of cocaine in rats. Neuropsychopharmacology 32, 646–657 (2007).
Article PubMed Google Scholar
Bierut, L. J. et al. Familial transmission of substance dependence: alcohol, marijuana, cocaine, and habitual smoking: a report from the Collaborative Study on the Genetics of Alcoholism. Arch. Gen. Psychiatry 55, 982–988 (1998).
Article PubMed Google Scholar
Hartz, S. M. et al. Increased genetic vulnerability to smoking at CHRNA5 in early-onset smokers. Arch. Gen. Psychiatry 69, 854–860 (2012).
Article PubMed PubMed Central Google Scholar
Lubke, G. H., Stephens, S. H., Lessem, J. M., Hewitt, J. K. & Ehringer, M. A. The CHRNA5/A3/B4 gene cluster and tobacco, alcohol, cannabis, inhalants and other substance use initiation: replication and new findings using mixture analyses. Behav. Genet. 42, 636–646 (2012).
Article PubMed PubMed Central Google Scholar
Ibsen, M. S., Connor, M. & Glass, M. Cannabinoid CB1 and CB2 receptor signaling and bias. Cannabis Cannabinoid Res. 2, 48–60 (2017).
Article PubMed PubMed Central Google Scholar
Cheung, C. P. et al. Cannabis inhalation acutely reduces muscle sympathetic nerve activity in humans. Circulation 146, 1972–1974 (2022).
Article PubMed Google Scholar
Download references
The authors are supported by the Heart and Stroke Barnett-Ivey Chair (to M.C.), the Tobacco-Related Disease Research Program (TRDRP, T34FT8070) and the American Heart Association (AHA, 23DIVSUP1076489) (to N.J.-T.), the Stanford Cardiovascular Institute, TRDRP (27IR-0012), Gootter-Jensen Foundation and the AHA (20YVNR3500014) (to J.C.W.).
Stanford Cardiovascular Institute, Stanford, CA, USA
Mark Chandy, Nerea Jimenez-Tellez & Joseph C. Wu
Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA, USA
Mark Chandy, Nerea Jimenez-Tellez & Joseph C. Wu
Department of Medicine, Western University, London, Ontario, Canada
Mark Chandy
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
You can also search for this author in PubMed Google Scholar
The authors contributed substantially to all aspects of the manuscript.
Correspondence to Mark Chandy or Joseph C. Wu.
M.C. is a consultant for Greenstone Biosciences. J.C.W. is a co-founder and on the Scientific Advisory Board of Greenstone Biosciences. N.J.-T. declares no competing interests.
Nature Reviews Cardiology thanks Emilie Jouanjus, George Kunos and Pal Pacher for their contribution to the peer review of this work.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
Reprints and permissions
Chandy, M., Jimenez-Tellez, N. & Wu, J.C. The relationship between cannabis and cardiovascular disease: clearing the haze. Nat Rev Cardiol (2025). https://doi.org/10.1038/s41569-025-01121-6
Download citation
Accepted:
Published:
DOI: https://doi.org/10.1038/s41569-025-01121-6
Anyone you share the following link with will be able to read this content:
Sorry, a shareable link is not currently available for this article.
Provided by the Springer Nature SharedIt content-sharing initiative
Advertisement
© 2025 Springer Nature Limited
Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.